Premium
Safety of kanamycin aerosol
Author(s) -
Lifschitz Martin I.,
Denning Carolyn R.
Publication year - 1971
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197112191
Subject(s) - kanamycin , cystic fibrosis , saline , sputum , aerosol , pharmacology , medicine , chemistry , chromatography , anesthesia , pathology , biochemistry , antibiotics , tuberculosis , organic chemistry
Three aspects of the pharmacology of kanamycin aerosol were investigated in normal subjects and in patients with cystic fibrosis. Absorption of kanamycin from the tracheobronchial tree was found to be so low that doses of 250 mg. per treatment appear safe, even in children. Aerosols containing 125 mg. per milliliter of kanamycin caused no greater decrease in the one‐second forced expiratory volume than did aerosols of saline alone. In vitro studies with cystic fibrosis sputum revealed that kanamycin had a viscosity reducing effect greater than that of water or saline.